further confirmed by DEPT 13C NMR experiments conducted
on 13C-labeled 3a prepared from 13C-ynone 1a (see the
Supporting Information).
was observed in the crude reaction mixture although many
other reactions, such as [2+2] cycloaddition of iminophos-
phorane with ynone7 or aziridine formation from intramo-
lecular reaction of 2-iminophosphorane alcohols,8 might have
occurred.
Chiral HPLC analysis of products 3a and 3g confirmed
that no racemization of the chiral centers occurred during
the reaction. We contemplated that a possible application of
this chemistry would be found in the synthesis of chiral
ligands by using diynones as starting material.
Our interest was focused on the preparation of 2,6-
bis(oxazepinyl)pyridines that are interesting 7-membered
analogues of the well-known pybox ligands.9 2,6-(diynone)-
pyridines 1b and 1c were therefore prepared from 2,6-
pyridinedicarbonyl dichloride according to a described pro-
tocole10 and reacted with (S)-2-azido-3-phenyl-1-propanol
in the presence of PBu3. Double cyclization occurred
efficiently affording the desired chiral ligands 3k and 3l with
moderate to excellent yields (Scheme 3).
The preparation of such 7-membered heterocycles 3 has
been only sporadically described despite their reported
biological activities.5 To the best of our knowledge, the
condensation of 2-amino alcohols with ꢀ-diketones is the
only reported one-step method leading to 2,3-dihydro-1,4-
oxazepines.6 This method suffers, however, from severe
drawbacks: yields are often low and only symmetrical
ꢀ-diketones should be used. Another simple route to ox-
azepines would have been the direct condensation of 2-amino
alcohols with ynones. However, all attemps conducted in
our laboratory to run such a reaction failed. Treatment of
1a with 2-benzylaminoethanol in the presence or absence
of catalytic amounts of Bro¨nsted or Lewis acids gave
complex mixtures. N-Michael adduct was the major isolated
product (5-30% yield), and no trace of oxazepine 3a was
observed.
Consequently, we decided to explore further the scope and
limitation of this phosphine-mediated reaction using a panel
of starting reagents (Scheme 2). The reaction proceeded
Scheme 3. Preparation of Bis-oxazepines Pybox Analogues
Scheme 2. Phosphine-Mediated Synthesis of
2,3-Dihydro-1,4-oxazepines 3
During the course of this study an unexpected rearrange-
ment was discovered when 2-phenyl-2-azido-1-ethanol 2b
was used as starting reagent. Upon reaction with ynone 1a
and PBu3 at room temperature, no trace of oxazepine
derivative was observed and 1,3-oxazine 4a was obtained
in high yield (Scheme 4). The structure of 4a was assigned
by comparison to published NMR data11 and further proven
by X-ray crystallography (see the Supporting Information).
To investigate whether or not this rearrangement is
general, we conducted a series of reactions involving azido
(6) (a) Soloshonok, V. A.; Ohkura, H.; Yasumoto, M. J. Fluor. Chem.
2006, 127, 708–711. (b) Soloshonok, V. A.; Ohkura, H.; Yasumoto, M.
MendeleeV Commun. 2006, 16, 165–167. (c) Lozada, M. C.; Enriquez, R. G.;
Soriano-Garcia, M.; Toscano, R. A.; Gnecco, D. J. Chem. Crystallogr. 2007,
37, 119–133.
smoothly at room temperature with a series of substrates
including heterocyclic ynones and disubstituted azido alco-
hols. It is quite remarkable that in all cases only one product
(7) (a) Palacios, F.; Alonso, C.; Pagalday, J.; Ochoa de Retana, A. M.;
Rubiales, G. Org. Biomol. Chem. 2003, 1, 1112–1118. (b) Palacios, F.;
Ochoa de Retana, A. M.; Pagalday, J. Tetrahedron 1999, 55, 14451–14458.
(8) Ittah, Y.; Sasson, Y.; Shahak, I.; Tsaroom, S.; Blum, J. J. Org. Chem.
1978, 43, 4271–4273.
(5) (a) McEvoy, F. J.; Greenblatt, E. N.; Osterberg, A. C.; Allen, G. R.,
Jr. J. Med. Chem. 1970, 13, 295–297. (b) Yale, H. L.; Sowinski, F. J. Med.
Chem. 1964, 7, 609–614. (c) Yale, H. L.; Beer, B.; Pluscec, J.; Spitzmiller,
E. R. J. Med. Chem. 1970, 13, 713–722. (d) Yale, H. L.; Sowinski, F.
J. Med. Chem. 1967, 10, 1022–1025. (e) Allen, R. C.; Reitano, P. A.;
Urbach, H. J. Med. Chem. 1978, 21, 838–841. (f) Pan, W.; Liu, H.; Xu,
Y.-J.; Chen, X.; Kim, K. H.; Milligan, D. L.; Columbus, J.; Hadari, Y. R.;
Kussie, P.; Wong, W. C.; Labelle, M. Bioorg. Med. Chem. Lett. 2005, 15,
5474–5477.
(9) For a review on pybox ligands see: (a) Nishiyama, H. AdV. Catal.
Processes 1997, 2, 153–188. (b) Desimoni, G.; Faita, G.; Quadrelli, P. Chem.
ReV. 2003, 103, 3119–3154.
(10) Cox, R. J.; Ritson, D. J.; Dane, T. A.; Berge, J.; Charmant, J.;
Kantacha, A. Chem. Commun. 2005, 1037.
(11) Manning, J. R.; Davies, H. M. L. Tetrahedron 2008, 64, 6901–
6908.
Org. Lett., Vol. 12, No. 1, 2010
41